Please assess the completion status of the following clinical trial:

Trial Title: Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~To be eligible to participate in this study, a subject must satisfy all of the following criteria:~1. The subject must be a healthy adult aged 18-65 years, and weighing at least 50 kg.~2, The subject must have normal renal function (creatinine \<1.5 mg/dL; \<1 plus proteinuria); normal hepatic function (bilirubin \< 1.5 mg/dL); normal hematologic function (WBC greater than or equal to 2500/mm(3); granulocytes greater than or equal to 1200/mm(3); platelets greater than or equal to 120,000; hematocrit greater than or equal to 38).~3. A female of childbearing potential may be entered if she is using 1 or 2 forms of effective contraception (depending on the type of contraception), and has a negative serum pregnancy test within 1 week of beginning G-CSF administration. She must continue with the effective contraception 3 months after receiving plerixafor~4. The subject must be willing to allow blood cell samples to be stored.~EXCLUSION CRITERIA:~A subject will be ineligible to participate in this study if any of the following criteria are met:~1. The subject has a temperature \> 38 degrees Celsius, or WBC \> 9000/mm(3).~2. A female who is pregnant or lactating as determined by history and/or pregnancy test.~3. The subject has a history of vasculitis, uncontrolled hypertension, or symptomatic coronary artery disease, or similar disorders.~4. The subject has a positive test result for any of the following: human immunodeficiency virus (HIV) I \& II antibody, hepatitis C virus (HCV) antibody, hepatitis B soluble antigen (HBSAg), or the rapid plasma reagin (RPR) test for syphilis.~5. The subject lacks peripheral venous access in arm veins adequate for apheresis.~6. The subject is currently participating in other research studies.~7. The subject may be excluded at the discretion of the Principal Investigator (PI).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: None): Any healthy volunteers that are eligible to donate blood.

Based on this trial design, predict the completion outcome and termination type (if applicable).